Skip to main navigation

Top Menu

About Us
Our Science
Pipeline
Partnering
Investors & Media
Careers
Contact

Investors & Media

Press Releases

Year

Entasis Therapeutics to Participate in the BMO 2020 Prescriptions for Success Healthcare Conference

Jun 18, 2020

Entasis Therapeutics Completes Closing of Second Tranche of $35M Private Placement with Innoviva

Jun 11, 2020

Entasis Therapeutics Reports First Quarter 2020 Financial Results and Business Update

May 07, 2020

Entasis Therapeutics Completes Initial Closing of $35M Private Placement with Innoviva

Apr 22, 2020

Entasis Therapeutics Reports Full Year 2019 Financial Results and Business Update

Mar 11, 2020

Entasis Therapeutics Reports Third Quarter 2019 Financial Results and Provides Business Update

Nov 14, 2019

Entasis Therapeutics Appoints Dr. David Altarac as Chief Medical Officer

Oct 30, 2019

Entasis Therapeutics to Present at the 28th Annual Credit Suisse Healthcare Conference

Oct 29, 2019

Entasis Therapeutics Announces Multiple Presentations at ID Week 2019

Oct 03, 2019

GARDP and Entasis Therapeutics Initiate Global Phase 3 Trial of Zoliflodacin, a First-in-Class Oral Antibiotic for the Treatment of Gonorrhea

Sep 30, 2019

Pagination

Current page 1
Page 2
Page 3
Page 4
Page 5
Page 6
Page 7
Next page
Last page

Displaying 1 - 10 of 63

Toolkit

Print page
RSS Feeds
Email Alerts
Search

Investor Relations

Corporate Overview
News & Events
- Press Releases
- Events & Presentations
Stock Information
SEC Filings
Corporate Governance
Investor Resources

"Antibiotic resistance is a worldwide problem that is constantly growing. New forms of resistance can spread quickly and across continents. At Entasis, we discover and develop novel antibacterials to address the serious medical need posed by multi-drug resistant bacterial infections."

— Ruben Tommasi, Chief Scientific Officer

©2020 Entasis Therapeutics Inc.

Terms of Use | Privacy Policy